pharmafocusasiaMarch 27, 2019
Tag: Clinical Trials , NanoSmart Pharmaceuticals , SourcingLink.net
SourcingLink.net, Inc. (SNET), announced today that it entered into an exclusive worldwide licensing agreement with NanoSmart Pharmaceuticals, Inc. for the right to use NanoSmart’s nanoparticle platform technologies to develop and commercialize improved formulations of doxorubicin for the treatment of human cancers. The license includes access to one of NanoSmart's lead drug formulations, ANA- Conjugated Liposomal Doxorubicin, which has been previously granted Orphan Drug Designation by the US Food and Drug Administration. Under the terms of the agreement, NanoSmart will receive an upfront fee, restricted common shares of SNET stock, an annual maintenance fee, and a high single-digit royalty on net sales of formulations that incorporate NanoSmart's intellectual property.
SourcingLink.net stated, "We are pleased to have licensed the application of NanoSmart’s tumor-targeting technology to improve doxorubicin formulations. This is a significant extension of our oncology product portfolio to address the growing need for improved cancer therapies. We look forward to initiating nonclinical development, clinical trials, FDA submission, and commercialization of a tumor-targeting drug product and to explore combination with our proprietary liquid biopsy platform to potentially deliver personalized treatment paradigms that are safer and more effective than existing options."
Doxorubicin is a well-established anthracycline chemotherapeutic drug used for treating a broad range of cancers such as ovarian, breast, bladder, Kaposi's sarcoma, lymphomas, thyroid, neuroblastoma and lung cancers. Commercializing a targeted doxorubicin formulation provides the opportunity to impact millions of cancer patients worldwide and to provide better therapy options for the growing global cancer population, including rare cancers with unmet needs. Dr. James Smith, President and CEO of NanoSmart Pharmaceuticals, stated "Our initial non-clinical testing on ANA-conjugated liposomal doxorubicin is very promising, and we believe that SNET’s involvement will enable the efficient commercialization of one of our lead candidate formulations and further validate the performance of our proprietary drug delivery platform technologies."
Register as Visitor to CPhI China 2019!
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: